Cryo-Cell International, Inc.(CCEL)Earnings, Financials & Key Ratios

CCEL•NASDAQ

$3.53

$28M mkt cap·70.6× P/E·Price updated May 6, 2026

SectorHealthcare IndustryHealthcare Facilities Sub-IndustryHealthcare staffing and facility services

AboutCryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Show more

Revenue$32M+2.0%
EBITDA$4M+137.4%
Net Income$402K+104.2%
EPS (Diluted)0.05+104.4%
Gross Margin75.15%+2.9%
EBITDA Margin12.39%+136.7%
Operating Margin10.88%+127.7%
Net Margin1.26%+104.1%
Interest Coverage1.87+118.8%

Technical→

CCEL Key Insights

Cryo-Cell International, Inc. (CCEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 208.4%
✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Profits declining 29.4% over 5 years
✗Dividend payout exceeds 100% of earnings
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CCEL Price & Volume

Cryo-Cell International, Inc. (CCEL) stock price & volume — 10-year historical chart

Loading chart...

CCEL Growth Metrics

Cryo-Cell International, Inc. (CCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years4.74%

5 Years0.11%

3 Years3.46%

TTM-0.29%

Profit CAGR

10 Years-3.15%

5 Years-29.39%

3 Years-42.21%

TTM104.48%

EPS CAGR

10 Years0%

5 Years-28.63%

3 Years-41.52%

TTM93.41%

Return on Capital

10 Years19.86%

5 Years5.49%

3 Years-3.63%

Last Year8.34%

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
VCELVericel CorporationProduct Competitor	1.86B	36.78	114.94	16.45%	5.98%	4.66%	0.27
BLFSBioLife Solutions, Inc.Product Competitor	1.05B	21.75	-87	16.97%	-12.61%	-3.26%	0.03
IARTIntegra LifeSciences Holdings CorporationProduct Competitor	1.09B	14.00	-2.08	1.53%	-30.15%	-47.65%	1.95
OSUROraSure Technologies, Inc.Product Competitor	215.9M	3.00	-3.19	-38.1%	-61.93%	-19.46%	0.04
NTRANatera, Inc.Product Competitor	29.58B	215.09	-140.58	56.75%	-14.61%	-24.69%	0.16
BDXBecton, Dickinson and CompanySupply Chain	52.45B	144.76	24.83	8.23%	8.01%	6.93%	0.76
TECHBio-Techne CorporationSupply Chain	7.42B	47.41	103.05	5.23%	9.05%	5.48%	0.23
FELEFranklin Electric Co., Inc.Supply Chain	4.46B	100.98	31.07	5.44%	6.91%	11.44%	0.21

Compare CCEL vs Peers

Cryo-Cell International, Inc. (CCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs VCEL

Most directly comparable listed peer for CCEL.

Scale Benchmark

vs BDX

Larger-name benchmark to compare CCEL against a more recognizable public peer.

Peer Set

Compare Top 5

vs VCEL, BLFS, IART, OSUR

CCEL Income Statement

Cryo-Cell International, Inc. (CCEL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Nov'16	Nov'17	Nov'18	Nov'19	Nov'20	Nov'21	Nov'22	Nov'23	Nov'24	TTM
Sales/Revenue	23.13M	25.38M	29.22M	31.82M	31.15M	28.88M	30.34M	31.34M	31.99M	31.75M
Revenue Growth %	9.66%	9.76%	15.1%	8.89%	-2.1%	-7.26%	5.03%	3.32%	2.05%	-0.29%
Cost of Goods Sold	5.77M	6.72M	8.54M	10.04M	9.66M	8.99M	8.79M	8.44M	7.95M	7.28M
COGS % of Revenue	24.97%	26.49%	29.23%	31.54%	31.01%	31.12%	28.98%	26.93%	24.85%	-
Gross Profit	17.35M▲ 0%	18.66M▲ 7.5%	20.68M▲ 10.8%	21.78M▲ 5.3%	21.49M▼ 1.3%	19.9M▼ 7.4%	21.54M▲ 8.3%	22.9M▲ 6.3%	24.04M▲ 5.0%	24.47M▲ 0%
Gross Margin %	75.03%	73.51%	70.77%	68.46%	68.99%	68.88%	71.02%	73.07%	75.15%	77.07%
Gross Profit Growth %	12.24%	7.53%	10.82%	5.33%	-1.33%	-7.42%	8.29%	6.3%	4.96%	-
Operating Expenses	14.93M	13.65M	15.9M	15.13M	13.83M	15.88M	17.52M	35.26M	20.56M	20.14M
OpEx % of Revenue	64.56%	53.79%	54.43%	47.55%	44.4%	54.97%	57.75%	112.49%	64.27%	-
Selling, General & Admin	14.72M	13.48M	15.63M	14.89M	14.29M	14.63M	15.58M	17.12M	18.52M	18.78M
SG&A % of Revenue	63.66%	53.11%	53.5%	46.8%	45.89%	50.63%	51.36%	54.61%	57.9%	-
Research & Development	53.1K	41.16K	91.84K	30.14K	23.85K	49.87K	384.79K	1.17M	1.24M	596.11K
R&D % of Revenue	0.23%	0.16%	0.31%	0.09%	0.08%	0.17%	1.27%	3.74%	3.88%	-
Other Operating Expenses	154.67K	131.61K	180.26K	206.24K	-489.53K	1.22M	1.55M	16.92M	794.32K	762.59K
Operating Income	433.59K▲ 0%	5.01M▲ 1054.6%	5.19M▲ 3.7%	5.06M▼ 2.4%	7.66M▲ 51.3%	4.02M▼ 47.6%	4.02M▲ 0.2%	-12.3M▼ 405.7%	3.48M▲ 128.3%	4.33M▲ 0%
Operating Margin %	1.87%	19.72%	17.76%	15.91%	24.6%	13.91%	13.27%	-39.26%	10.88%	13.63%
Operating Income Growth %	-85.22%	1054.59%	3.66%	-2.44%	51.33%	-47.55%	0.16%	-405.73%	128.29%	-
EBITDA	720.24K	5.24M	5.51M	5.46M	8.3M	5.34M	5.83M	-10.59M	3.96M	5.69M
EBITDA Margin %	3.11%	20.63%	18.85%	17.17%	26.64%	18.5%	19.23%	-33.8%	12.39%	17.92%
EBITDA Growth %	-77.31%	627.01%	5.16%	-0.77%	51.86%	-35.59%	9.15%	-281.59%	137.42%	147.34%
D&A (Non-Cash Add-back)	286.65K	230K	317.33K	401.31K	635.98K	1.33M	1.81M	1.71M	483.52K	1.36M
EBIT	-1.53M	4.93M	5.16M	5.09M	6.58M	3.99M	4.84M	-12.13M	939.44K	3.78M
Net Interest Income	-947.34K	-1.3M	-1.55M	-1.7M	-1.54M	-1.38M	-1.52M	-1.24M	-1.86M	-2.33M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	947.34K	1.3M	1.55M	1.7M	1.54M	1.38M	1.52M	1.24M	1.86M	2.33M
Other Income/Expense	-2.91M	-1.38M	-1.57M	-1.67M	-2.62M	-1.41M	-705.52K	-1.06M	-676.16K	-2.87M
Pretax Income	-2.48M▲ 0%	3.62M▲ 246.1%	3.62M▼ 0.2%	3.39M▼ 6.3%	5.04M▲ 48.6%	2.61M▼ 48.2%	3.32M▲ 27.1%	-13.36M▼ 502.7%	2.8M▲ 121.0%	1.45M▲ 0%
Pretax Margin %	-10.72%	14.28%	12.38%	10.66%	16.18%	9.04%	10.94%	-42.64%	8.77%	4.57%
Income Tax	-1.16M	1.31M	4.47M	1.1M	1.41M	527.71K	547.54K	-3.84M	2.4M	1.05M
Effective Tax Rate %	46.75%	36.11%	123.63%	32.45%	28.07%	20.21%	16.5%	28.75%	85.66%	72.49%
Net Income	-1.32M▲ 0%	2.32M▲ 275.3%	-854.82K▼ 136.9%	2.29M▲ 368.0%	3.62M▲ 58.2%	2.08M▼ 42.5%	2.77M▲ 33.0%	-9.52M▼ 443.6%	402.1K▲ 104.2%	399.61K▲ 0%
Net Margin %	-5.71%	9.12%	-2.93%	7.2%	11.64%	7.21%	9.14%	-30.38%	1.26%	1.26%
Net Income Growth %	-116.29%	275.28%	-136.92%	367.98%	58.23%	-42.52%	33.02%	-443.57%	104.22%	104.48%
Net Income (Continuing)	-1.32M	2.32M	-854.82K	2.29M	3.62M	2.08M	2.77M	-9.52M	402.1K	399.61K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.16▲ 0%	0.30▲ 287.5%	-0.11▼ 136.7%	0.27▲ 345.5%	0.45▲ 66.7%	0.25▼ 44.4%	0.33▲ 32.0%	-1.14▼ 445.5%	0.05▲ 104.4%	0.05▲ 0%
EPS Growth %	-119.28%	287.5%	-136.67%	345.45%	66.67%	-44.44%	32%	-445.45%	104.39%	93.41%
EPS (Basic)	-0.16	0.33	-0.11	0.29	0.48	0.26	0.33	-1.14	0.05	-
Diluted Shares Outstanding	8.11M	7.65M	7.46M	8.41M	8.14M	8.36M	8.48M	8.34M	8.21M	8.07M
Basic Shares Outstanding	8.11M	7.06M	7.46M	8.41M	8.14M	8.14M	8.47M	8.34M	8.13M	8.06M
Dividend Payout Ratio	-	-	-	-	-	-	276.85%	-	502.5%	-

CCEL Balance Sheet

Cryo-Cell International, Inc. (CCEL) balance sheet — assets, liabilities & shareholders' equity

Line item	Nov'16	Nov'17	Nov'18	Nov'19	Nov'20	Nov'21	Nov'22	Nov'23	Nov'24	TTM
Total Current Assets	9.01M	12.74M	29.54M	15.39M	18.56M	15.78M	9.61M	9.45M	12.55M	11.67M
Cash & Short-Term Investments	4.12M	6.72M	6.92M	7.45M	10.45M	8.34M	1.72M	980.25K	3.5M	3.22M
Cash Only	3.5M	6.28M	6.04M	6.54M	10.36M	8.26M	1.7M	406.07K	560.96K	265.21K
Short-Term Investments	624.22K	439.32K	875.69K	904.05K	88.48K	75.41K	17.62K	574.18K	2.94M	2.96M
Accounts Receivable	4.05M	5.13M	5.87M	6.1M	6.32M	5.25M	6.04M	6.58M	7.31M	0
Days Sales Outstanding	63.96	73.7	73.3	69.95	74.09	66.38	72.72	76.58	83.41	61.66
Inventory	361.14K	314.57K	16.04M	1.08M	927.32K	921.21K	851.23K	768.88K	657.7K	655.25K
Days Inventory Outstanding	22.83	17.07	685.4	39.44	35.05	37.4	35.34	33.24	30.2	34.1
Other Current Assets	78.45K	206.14K	254.47K	260.4K	244.7K	711.21K	426.88K	512.06K	454.6K	7.8M
Total Non-Current Assets	10.53M	11.17M	12.85M	27.5M	27.64M	44.88M	55.28M	51.77M	52.12M	51.5M
Property, Plant & Equipment	979.46K	882.38K	1.49M	1.85M	1.94M	4.15M	14.21M	22.03M	22.7M	22.11M
Fixed Asset Turnover	23.61x	28.77x	19.57x	17.23x	16.06x	6.97x	2.14x	1.42x	1.41x	1.42x
Goodwill	0	0	1.94M	1.94M	1.94M	1.94M	1.94M	1.94M	1.94M	1.94M
Intangible Assets	261K	226.42K	1.34M	1.25M	1.53M	16.21M	15.15M	989.12K	921.25K	874.23K
Long-Term Investments	0	0	308K	308K	308K	308K	308K	0	0	0
Other Non-Current Assets	25.5K	28.89K	113.89K	13.07M	11.56M	10.26M	9.92M	6.31M	5.76M	23.06M
Total Assets	19.54M▲ 0%	23.91M▲ 22.4%	42.39M▲ 77.3%	42.89M▲ 1.2%	46.2M▲ 7.7%	60.66M▲ 31.3%	64.89M▲ 7.0%	61.22M▼ 5.7%	64.68M▲ 5.6%	63.17M▲ 0%
Asset Turnover	1.18x	1.06x	0.69x	0.74x	0.67x	0.48x	0.47x	0.51x	0.49x	0.49x
Asset Growth %	0.21%	22.37%	77.29%	1.17%	7.73%	31.3%	6.97%	-5.65%	5.65%	13.34%
Total Current Liabilities	13.11M	13.94M	15.43M	15.43M	16.41M	21.07M	19.48M	20.86M	21.6M	18.45M
Accounts Payable	1.49M	1.93M	1.26M	1.37M	957.39K	1.49M	1.61M	3.17M	1.88M	2.61M
Days Payables Outstanding	93.89	104.68	53.93	49.79	36.18	60.49	66.64	137.25	86.44	118.84
Short-Term Debt	0	0	0	3.1M	3.1M	1.9M	2.42M	1.39M	3.69M	3.63M
Deferred Revenue (Current)	7.07M	7.43M	8.37M	8.88M	9.18M	9.36M	9.59M	9.7M	9.79M	38.54M
Other Current Liabilities	2M	2M	3.1M	0	0	4.96M	1.98M	1.2M	1.42M	2.46M
Current Ratio	0.69x	0.91x	1.91x	1.00x	1.13x	0.75x	0.49x	0.45x	0.58x	0.58x
Quick Ratio	0.66x	0.89x	0.87x	0.93x	1.07x	0.71x	0.45x	0.42x	0.55x	0.55x
Cash Conversion Cycle	-7.1	-13.91	704.77	59.6	72.96	43.3	41.41	-27.43	27.17	-23.08
Total Non-Current Liabilities	21.84M	22.47M	35.87M	34.41M	32.45M	35.4M	46.93M	51.39M	56.29M	59.55M
Long-Term Debt	0	0	0	0	2.84M	0	8.58M	8.43M	8.31M	577.2K
Capital Lease Obligations	0	0	0	0	23.63K	610.99K	313.3K	851.94K	505.05K	505.05K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9.24M	6.72M	15.55M	10.78M	2.38M	3.52M	2.04M	919.23K	922.02K	166.92M
Total Liabilities	34.95M	36.41M	51.3M	49.84M	48.87M	56.48M	66.41M	72.25M	77.89M	78M
Total Debt	9.82M	7.3M	12.94M	8.96M	6.24M	2.82M	11.61M	10.9M	12.93M	4.21M
Net Debt	6.32M	1.02M	6.9M	2.42M	-4.12M	-5.44M	9.91M	10.49M	12.37M	3.95M
Debt / Equity	-	-	-	-	-	0.67x	-	-	-	-0.28x
Debt / EBITDA	13.63x	1.39x	2.35x	1.64x	0.75x	0.53x	1.99x	-	3.26x	0.74x
Net Debt / EBITDA	8.77x	0.19x	1.25x	0.44x	-0.50x	-1.02x	1.70x	-	3.12x	3.12x
Interest Coverage	0.46x	3.84x	3.35x	2.97x	4.96x	2.91x	2.64x	-9.95x	1.87x	1.62x
Total Equity	-15.41M▲ 0%	-12.5M▲ 18.9%	-8.91M▲ 28.8%	-6.95M▲ 22.0%	-2.67M▲ 61.7%	4.18M▲ 257.0%	-1.52M▼ 136.4%	-11.03M▼ 623.7%	-13.22M▼ 19.8%	-14.83M▲ 0%
Equity Growth %	-210.51%	18.89%	28.75%	21.95%	61.67%	257%	-136.43%	-623.69%	-19.81%	-161.59%
Book Value per Share	-1.90	-1.63	-1.19	-0.83	-0.33	0.50	-0.18	-1.32	-1.61	-1.84
Total Shareholders' Equity	-15.41M	-12.5M	-8.91M	-6.95M	-2.67M	4.18M	-1.52M	-11.03M	-13.22M	-14.83M
Common Stock	125.04K	129K	135.96K	135.99K	136.34K	146.66K	148.48K	148.49K	148.7K	148.77K
Retained Earnings	-26.79M	-24.47M	-25.33M	-22.44M	-18.82M	-16.74M	-21.64M	-31.16M	-32.78M	-34.62M
Treasury Stock	-19.12M	-19.57M	-19.57M	-20.56M	-20.56M	-20.81M	-22.63M	-23.43M	-24.86M	0
Accumulated OCI	34.41K	40.87K	340.98K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

CCEL Cash Flow Statement

Cryo-Cell International, Inc. (CCEL) cash flow — operating, investing & free cash flow history

Line item	Nov'16	Nov'17	Nov'18	Nov'19	Nov'20	Nov'21	Nov'22	Nov'23	Nov'24	TTM
Cash from Operations	4.99M	5.72M	5.33M	6.32M	8.47M	7.93M	8.57M	8.92M	6.01M	6.01M
Operating CF Margin %	21.57%	22.53%	18.25%	19.87%	27.18%	27.44%	28.26%	28.46%	18.79%	-
Operating CF Growth %	2.81%	14.64%	-6.73%	18.56%	33.9%	-6.38%	8.16%	4.05%	-32.61%	275.79%
Net Income	-1.32M	2.32M	-854.82K	2.29M	3.62M	2.08M	2.77M	-9.52M	402.1K	399.61K
Depreciation & Amortization	286.65K	230K	317.33K	401.31K	635.98K	1.33M	1.81M	1.71M	1.02M	1.38M
Stock-Based Compensation	1.77M	971.73K	478.38K	397.77K	622.12K	301.62K	461.35K	816.64K	781.13K	447.08K
Deferred Taxes	-1.91M	-774.81K	2.38M	-1.52M	-1.28M	-1.65M	-1.73M	-6.75M	-309.27K	0
Other Non-Cash Items	4.62M	202.45K	583.8K	2.47M	1.11M	1M	1.01M	16.68M	417K	1.5M
Working Capital Changes	1.54M	2.77M	2.43M	2.28M	3.76M	4.86M	4.25M	5.99M	3.7M	3.51M
Change in Receivables	-1.62M	-1.15M	-1.35M	-997.12K	-828.59K	532.79K	-1.72M	6.58M	-2M	-1.09M
Change in Inventory	114.47K	46.58K	316.65K	-27.42K	454.94K	210.28K	490K	0	429.18K	299.7K
Change in Payables	329.56K	443.11K	-666.89K	107.46K	-411.72K	532.38K	115.53K	0	-423.72K	611.37K
Cash from Investing	-369.73K	93.03K	-11.28M	-690.66K	357.49K	-6.95M	-15.28M	-8.14M	-4.88M	-1.8M
Capital Expenditures	-342.98K	-98.33K	-646.16K	-662.29K	-449.96K	-6.95M	-17.17M	-6.84M	-2.4M	-171.6K
CapEx % of Revenue	1.48%	0.39%	2.21%	2.08%	1.44%	24.07%	56.59%	21.82%	7.51%	-
Acquisitions	0	0	-10.5M	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-26.75K	191.36K	-136.25K	0	0	0	1.87M	-800K	-1.1M	-18.33K
Cash from Financing	-5.27M	-3.03M	5.71M	-5.13M	-5M	-3.07M	147.86K	-2.07M	-979.12K	-4.49M
Debt Issued (Net)	9.27M	-2.65M	5.71M	-4.1M	-3.1M	-4.1M	9.29M	-1.21M	2.16M	4.29M
Equity Issued (Net)	-1000K	-446.62K	0	-992.24K	0	-249.38K	-1000K	-799.04K	-1000K	-88.62K
Dividends Paid	0	0	0	0	0	0	-7.67M	0	-2.02M	-3.23M
Share Repurchases	-10.81M	-446.62K	0	-992.24K	0	-249.38K	-1.82M	-799.04K	-1.42M	-169.5K
Other Financing	-3.74M	64.7K	1.63K	-39.3K	-1.9M	1.28M	354.77K	-67.5K	304.4K	-5.46M
Net Change in Cash	-652.28K▲ 0%	2.78M▲ 526.1%	-239.12K▼ 108.6%	501K▲ 309.5%	3.82M▲ 662.5%	-2.1M▼ 154.9%	-6.56M▼ 212.6%	-1.3M▲ 80.2%	154.89K▲ 111.9%	67.77K▲ 0%
Free Cash Flow	4.64M▲ 0%	5.62M▲ 21.0%	4.69M▼ 16.6%	5.66M▲ 20.8%	8.02M▲ 41.6%	974.92K▼ 87.8%	-8.6M▼ 981.7%	1.28M▲ 114.9%	3.61M▲ 181.6%	6.05M▲ 0%
FCF Margin %	20.08%	22.14%	16.04%	17.79%	25.74%	3.38%	-28.33%	4.09%	11.28%	19.06%
FCF Growth %	-2.07%	20.99%	-16.6%	20.77%	41.61%	-87.84%	-981.69%	114.9%	181.64%	244.79%
FCF per Share	0.57	0.73	0.63	0.67	0.98	0.12	-1.01	0.15	0.44	0.44
FCF Conversion (FCF/Net Income)	-3.78x	2.47x	-6.24x	2.76x	2.34x	3.80x	3.09x	-0.94x	14.95x	15.14x
Interest Paid	0	0	0	0	0	1.04M	1.26M	1.81M	1.98M	986.44K
Taxes Paid	0	0	0	0	0	3.53M	1.57M	1.82M	2.72M	2.53M

CCEL Key Ratios

Cryo-Cell International, Inc. (CCEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
Return on Equity (ROE)	-	-	-	-	-	274.3%	208.38%	-	-	-2.74%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	84.69%	-235.27%	-	-67.27%
Gross Margin	75.03%	73.51%	70.77%	68.46%	68.99%	68.88%	71.02%	73.07%	75.15%	77.07%
Net Margin	-5.71%	9.12%	-2.93%	7.2%	11.64%	7.21%	9.14%	-30.38%	1.26%	1.26%
Debt / Equity	-	-	-	-	-	0.67x	-	-	-	-0.28x
Interest Coverage	0.46x	3.84x	3.35x	2.97x	4.96x	2.91x	2.64x	-9.95x	1.87x	1.62x
FCF Conversion	-3.78x	2.47x	-6.24x	2.76x	2.34x	3.80x	3.09x	-0.94x	14.95x	15.14x
Revenue Growth	9.66%	9.76%	15.1%	8.89%	-2.1%	-7.26%	5.03%	3.32%	2.05%	-0.29%

CCEL SEC Filings & Documents

Cryo-Cell International, Inc. (CCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 12, 2026·SEC

Material company update

Nov 12, 2025·SEC

Material company update

Oct 23, 2025·SEC

10-K Annual Reports

FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 28, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

FY 2026

Apr 14, 2026·SEC

FY 2025

Oct 15, 2025·SEC

FY 2025

Jul 15, 2025·SEC

CCEL Frequently Asked Questions

Cryo-Cell International, Inc. (CCEL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Cryo-Cell International, Inc. (CCEL) reported $31.7M in revenue for fiscal year 2024. This represents a 1076% increase from $2.7M in 1996.

Cryo-Cell International, Inc. (CCEL) grew revenue by 2.0% over the past year. Growth has been modest.

Yes, Cryo-Cell International, Inc. (CCEL) is profitable, generating $0.4M in net income for fiscal year 2024 (1.3% net margin).

Dividend & Returns

Yes, Cryo-Cell International, Inc. (CCEL) pays a dividend with a yield of 6.97%. This makes it attractive for income-focused investors.

Cryo-Cell International, Inc. (CCEL) generated $6.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CCEL

Cryo-Cell International, Inc. (CCEL) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Cryo-Cell International, Inc.(CCEL)Earnings, Financials & Key Ratios

CCEL Key Insights

✓Strengths

✗Weaknesses

CCEL Price & Volume

CCEL Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CCEL Peer Comparison

Compare CCEL vs Peers

vs VCEL

vs BDX

Compare Top 5

CCEL Income Statement

CCEL Balance Sheet

CCEL Cash Flow Statement

CCEL Key Ratios

CCEL SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

CCEL Frequently Asked Questions

Explore More CCEL

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation